Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD
NCT02270424 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 564
Last updated 2014-10-21
Summary
The aim of this study is to compare the effectiveness of two treatments for severe / very severe COPD patients: one, conventional medicine based on 2013 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines; the other, TCM treatments and conventional medicine, which have been evaluated and have certain effect.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Salmeterol / fluticasone (Seretide®)
According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
- DRUG
-
Bufeijianpi granule
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
- DRUG
-
Bufeiyishen granule
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
- DRUG
-
Yiqizishen granule
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
- DRUG
-
Placebo Bufeijianpi granule
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
- DRUG
-
Placebo Bufeiyishen granule
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
- DRUG
-
Placebo Yiqizishen granule
According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
Sponsors & Collaborators
-
Henan University of Traditional Chinese Medicine
lead OTHER
Principal Investigators
-
Jiansheng Li, Doctor · The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-10-31
- Primary Completion
- 2016-12-31
- Completion
- 2016-12-31
More Related Trials
-
Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis
NCT06676800 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF
NCT06914713 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD
NCT04675463 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07140328 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bufei Jianpi Granule for Delaying Pulmonary Function Decline in Early-Stage COPD
NCT03976700 ·Status: UNKNOWN ·Phase: PHASE3
-
The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis
NCT01769898 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07108699 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis
NCT02782312 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of COPD Standardized Management on COPD Exacerbation
NCT04664491 ·Status: RECRUITING ·Phase: NA
-
The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD
NCT01243788 ·Status: UNKNOWN ·Phase: PHASE4
-
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06527144 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
NCT07252908 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD
NCT02296047 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06035393 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation
NCT04509661 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients
NCT01796730 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients
NCT02093195 ·Status: UNKNOWN ·Phase: PHASE2
-
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
NCT05046795 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
NCT05987371 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Qingkepingchuan Granules Clinical Observation of Phlegm-Heat and Lung Depletion
NCT06143358 ·Status: COMPLETED ·Phase: NA
-
Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice
NCT04536402 ·Status: COMPLETED
-
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
NCT02343458 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
NCT07114120 ·Status: RECRUITING ·Phase: PHASE4
-
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
NCT06748079 ·Status: RECRUITING ·Phase: PHASE1